These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3796769)

  • 1. Isolation and characterization of an endogenous drug-binding inhibitor present in uremic serum.
    Mabuchi H; Nakahashi H
    Nephron; 1986; 44(4):277-81. PubMed ID: 3796769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding.
    Niwa T; Takeda N; Maeda K; Shibata M; Tatematsu A
    Clin Chim Acta; 1988 Apr; 173(2):127-38. PubMed ID: 3378354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of renal transplantation on a major endogenous ligand retained in uremic serum.
    Mabuchi H; Nakahashi H; Hamajima T; Aikawa I; Oka T
    Am J Kidney Dis; 1989 Jan; 13(1):49-54. PubMed ID: 2643310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):281-3. PubMed ID: 3137482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, a major endogenous ligand substance in uremic serum, by high-performance liquid chromatography with ultraviolet detection.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1987 Mar; 415(1):110-7. PubMed ID: 3584344
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification and quantification of a protein-bound ligand in uremic serum.
    Takeda N; Niwa T; Tatematsu A; Suzuki M
    Clin Chem; 1987 May; 33(5):682-5. PubMed ID: 3568353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia.
    Mabuchi H; Nakahashi H
    Clin Chim Acta; 1987 Jul; 167(1):89-96. PubMed ID: 3665090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
    Mabuchi H; Nakahashi H
    Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly sensitive simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry.
    Oda A; Suzuki Y; Sato B; Sato H; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Sep Sci; 2022 May; 45(10):1672-1682. PubMed ID: 35247297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Separation of albumin-binding ligands present in uremic serum by high-performance affinity chromatography.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1990 Aug; 529(2):424-30. PubMed ID: 2229260
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients.
    Sato M; Koyama M; Miyazaki T; Niwa T
    Nephron; 1996; 74(2):419-21. PubMed ID: 8893167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.
    Niwa T; Takeda N; Tatematsu A; Maeda K
    Clin Chem; 1988 Nov; 34(11):2264-7. PubMed ID: 3141084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
    Tsutsumi Y; Maruyama T; Takadate A; Shimada H; Otagiri M
    Nephron; 2000 May; 85(1):60-4. PubMed ID: 10773757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin.
    Henderson SJ; Lindup WE
    Biochem Pharmacol; 1990 Dec; 40(11):2543-8. PubMed ID: 2268372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of binding site of uremic toxins on human serum albumin.
    Sakai T; Takadate A; Otagiri M
    Biol Pharm Bull; 1995 Dec; 18(12):1755-61. PubMed ID: 8787801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid assay for furancarboxylic acid accumulated in uremic serum using high-performance liquid chromatography and on-line mass spectrometry.
    Niwa T; Kawagishi I; Ohya N
    Clin Chim Acta; 1994 Apr; 226(1):89-94. PubMed ID: 8070137
    [No Abstract]   [Full Text] [Related]  

  • 18. Isolation of inhibitors of ligand: albumin-binding from uremic body fluids and normal urine.
    Gulyassy PF; Bottini AT; Jarrard EA; Stanfel LA
    Kidney Int Suppl; 1983 Dec; 16():S238-42. PubMed ID: 6588258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid chromatographic tandem mass spectrometric assay for the uremic toxin 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in human plasma.
    Huang Y; Sun H; Frassetto L; Benet LZ; Lin ET
    Rapid Commun Mass Spectrom; 2006; 20(10):1611-4. PubMed ID: 16628600
    [No Abstract]   [Full Text] [Related]  

  • 20. Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients.
    De Smet R; Vogeleere P; Van Kaer J; Lameire N; Vanholder R
    J Chromatogr A; 1999 Jun; 847(1-2):141-53. PubMed ID: 10431358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.